1-(isothiocyanatomethyl)-2-phenylbenzene | 442689-74-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(isothiocyanatomethyl)-2-phenylbenzene
• 英文别名: 2-(isothiocyanatom-ethyl)-1,1’-biphenyl；2-(isothiocyanatomethyl)biphenyl；2-Phenylbenzyl isothiocyanate
• CAS: 442689-74-9
• 化学式: C₁₄H₁₁NS
• 分子量: 225.314
• InChiKey: GRVOXMXDKJRDHJ-UHFFFAOYSA-N

物化性质

• 沸点：
  140～145℃/1mm
• 密度：
  1.05±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  44.4
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT

反应信息

• 作为反应物：
  描述：

  1-(isothiocyanatomethyl)-2-phenylbenzene 、 (4-氯苯氧基)-乙酸肼 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.5h， 生成 1-(4-chlorophenoxyacetyl)-4-(2-phenylbenzyl)-thiosemicarbazide
  参考文献：
  名称：

  Aggrecanase-2 inhibitors based on the acylthiosemicarbazide zinc-binding group

  摘要：

  Osteoarthritis is a disabling disease characterized by the articular cartilage breakdown. Aggrecanases are potential therapeutic targets for the treatment of this pathology. At the starting point of this project, an acylthiosemicarbazide was discovered to inhibit aggrecanase-2. The acylthiosemicarbazide Zn binding group is also a convenient linker for library synthesis. A focused library of 920 analogs was thus prepared and screened to establish structure-activity relationships. The modification of the acylthiosemicarbazide was also explored. This strategy combining library design and discrete compounds synthesis yielded inhibitor 35, that is highly selective for aggrecanases over a panel of metalloproteases and inhibits the degradation of native fully glycosylated aggrecan. A docking study generated binding conformations explaining the structure activity relationships. (C) 2013 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2013.08.027
• 作为产物：
  描述：

  2-苯基苄胺 、 二吡啶硫碳酸酯 以 二氯甲烷 为溶剂， 反应 63.0h， 以77%的产率得到1-(isothiocyanatomethyl)-2-phenylbenzene
  参考文献：
  名称：

  功能化芳基和联芳基异硫氰酸酯的合成和抗人 MCF-7 细胞的评价

  摘要：

  显示了孵育 24 小时和 72 小时后异硫氰酸酯160对 MCF-7 细胞的剂量反应抗癌特性。这些图描绘了通过抗增殖和 ARE 诱导测定获得的数据；ARE 感应数据下方的区域带有阴影以提高清晰度（t=24 小时，浅灰色）。这项研究的结果确定了几种关键的结构-活性关系，以及异硫氰酸铅表现出有效的抗增殖特性。

  DOI：

  10.1002/cmdc.202200250

文献信息

• NOVEL HETEROARYL COMPOUND, ENANTIOMER, DIASTEREOMER OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND ANTIVIRAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT
  申请人：INSTITUT PASTEUR KOREA

  公开号：US20200031816A1

  公开（公告）日：2020-01-30

  The present invention relates to a novel heteroaryl compound, an enantiomer, a diastereomer or a pharmaceutically acceptable salt thereof, and an antiviral composition comprising the same as an active ingredient. The novel compounds represented by formula (I) or formula (II) according to the present invention are remarkably superior in antiviral activity against an influenza virus, and furthermore, have low cytotoxicity and thus low adverse effects on a human body. Therefore, a pharmaceutical composition containing the same as an active ingredient can be effectively used for the prevention or treatment of diseases caused by an influenza virus infection.

  本发明涉及一种新型杂环芳基化合物，其对映异构体、顺异构体或其药学上可接受的盐，以及包含其作为活性成分的抗病毒组合物。根据本发明的化合物代表的新型化合物（I）或化合物（II）在抗流感病毒活性方面明显优越，并且具有低细胞毒性，因此对人体的不良影响较低。因此，含有该化合物作为活性成分的药物组合物可有效用于预防或治疗由流感病毒感染引起的疾病。
• Novel substituted benzimidazol-2-ones as vasopressin receptor antagonists and neuropeptide Y modulators
  申请人：——

  公开号：US20030073842A1

  公开（公告）日：2003-04-17

  The invention is directed to substituted benzimidazol-2-ones of Formula I, 1 wherein A, X, Y, m, n, R 1 , R 2 , R 3 , R 4 , and R 5 are as described in the specification, which are useful as vasopressin receptor antagonists or Neuropeptide Y Modulators for treating conditions such as aggression, obsessive-compulsive disorders, hypertension, dysmenorrhea, congestive heart failure/cardiac insufficiency, coronary vasospasm, cardiac ischemia, liver cirrhosis, renal vasospasm, renal failure, edema, ischemia, stroke, thrombosis, water retention, nephrotic syndrome, central nervous injuries, obesity, anorexia, hyperglycemia, diabetes, anxiety, depression, asthma, memory loss, sexual dysfunction, disorders of sleep and other circadian rhythms, and Cushing's disease.

  该发明涉及Formula I的取代苯并咪唑酮，其中A、X、Y、m、n、R1、R2、R3、R4和R5如说明书中所述，其可用作抗利尿素受体拮抗剂或神经肽Y调节剂，用于治疗侵略性、强迫症障碍、高血压、痛经、充血性心力衰竭/心脏不全、冠状动脉痉挛、心肌缺血、肝硬化、肾血管痉挛、肾功能衰竭、水肿、缺血、中风、血栓形成、水潴留、肾症候群、中枢神经损伤、肥胖、厌食、高血糖、糖尿病、焦虑、抑郁、哮喘、记忆丧失、性功能障碍、睡眠障碍和其他生物钟紊乱症状，以及库欣综合征。
• ISOTHIOCYNATES AND GLUCOSINOLATE COMPOUNDS AND ANTI-TUMOR COMPOSITIONS CONTAINING SAME
  申请人：Rajski Scott R.

  公开号：US20130116203A1

  公开（公告）日：2013-05-09

  The present invention provides glucosinolate and isothiocyanate compounds and related methods for synthesizing these compounds and analogs. In certain embodiments, these glucosinolate and isothiocyanate compounds are useful and chemopreventive and or chemotherapeutic agents.

  本发明提供了葡萄糖苷和异硫氰酸酯化合物以及相关的合成这些化合物和类似物的方法。在某些实施例中，这些葡萄糖苷和异硫氰酸酯化合物可用作化学预防和/或化疗剂。
• ISOTHIOCYANATES AND GLUCOSINOLATE COMPOUNDS AND ANTI-TUMOR COMPOSITIONS CONTAINING SAME
  申请人：Rajski Scott R.

  公开号：US20080312164A1

  公开（公告）日：2008-12-18

  The present invention provides glucosinolate and isothiocyante compounds and related methods for synthesizing these compounds and analogs. In certain embodiments, these glucosinolate and isothiocyanate compounds are useful and chemopreventive and or chemotherapeutic agents.

  本发明提供了葡萄糖硫醇和异硫氰酸化合物及其相关合成方法和类似物。在某些实施例中，这些葡萄糖硫醇和异硫氰酸化合物是有用的化学预防和/或化学治疗剂。
• Heteroaryl compound, enantiomer, diastereomer or pharmaceutically acceptable salt thereof, and antiviral composition containing same as active ingredient
  申请人：INSTITUT PASTEUR KOREA

  公开号：US11149033B2

  公开（公告）日：2021-10-19

  The present invention relates to a novel heteroaryl compound, an enantiomer, a diastereomer or a pharmaceutically acceptable salt thereof, and an antiviral composition comprising the same as an active ingredient. The novel compounds represented by formula (I) or formula (II) according to the present invention are remarkably superior in antiviral activity against an influenza virus, and furthermore, have low cytotoxicity and thus low adverse effects on a human body. Therefore, a pharmaceutical composition containing the same as an active ingredient can be effectively used for the prevention or treatment of diseases caused by an influenza virus infection.

  本发明涉及一种新型杂芳基化合物、其对映体、非对映体或其药学上可接受的盐，以及以其为活性成分的抗病毒组合物。根据本发明，由式（I）或式（II）代表的新型化合物在抗流感病毒活性方面具有显著优势，而且细胞毒性低，因此对人体的不良影响小。因此，以其为活性成分的药物组合物可有效地用于预防或治疗由流感病毒感染引起的疾病。